553 related articles for article (PubMed ID: 22045636)
61. Molecular basis for the treatment of achondroplasia.
Yamanaka Y; Ueda K; Seino Y; Tanaka H
Horm Res; 2003; 60 Suppl 3():60-4. PubMed ID: 14671399
[TBL] [Abstract][Full Text] [Related]
62. FGFR3 mutation frequency in 324 cases from the International Skeletal Dysplasia Registry.
Xue Y; Sun A; Mekikian PB; Martin J; Rimoin DL; Lachman RS; Wilcox WR
Mol Genet Genomic Med; 2014 Nov; 2(6):497-503. PubMed ID: 25614871
[TBL] [Abstract][Full Text] [Related]
63. Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations.
Brodie SG; Kitoh H; Lachman RS; Nolasco LM; Mekikian PB; Wilcox WR
Am J Med Genet; 1999 Jun; 84(5):476-80. PubMed ID: 10360402
[TBL] [Abstract][Full Text] [Related]
64. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
Lee YC; Song IW; Pai YJ; Chen SD; Chen YT
Sci Rep; 2017 Feb; 7():43220. PubMed ID: 28230213
[TBL] [Abstract][Full Text] [Related]
65. Review of the recently defined molecular mechanisms underlying thanatophoric dysplasia and their potential therapeutic implications for achondroplasia.
Martínez-Frías ML; de Frutos CA; Bermejo E; Nieto MA;
Am J Med Genet A; 2010 Jan; 152A(1):245-55. PubMed ID: 20034074
[TBL] [Abstract][Full Text] [Related]
66. [Molecular basis of achondroplasia, hypochondroplasia, and thanatophoric dysplasia].
Moskalewski S; Hyc A; Osiecka-Iwan A; Strzelczyk P
Chir Narzadow Ruchu Ortop Pol; 2000; 65(3):327-33. PubMed ID: 11057021
[TBL] [Abstract][Full Text] [Related]
67. Acanthosis nigricans, hypochondroplasia, and FGFR3 mutations: Findings with five new patients, and a review of the literature.
Muguet Guenot L; Aubert H; Isidor B; Toutain A; Mazereeuw-Hautier J; Collet C; Bourrat E; Denis Musquer M; Barbarot S;
Pediatr Dermatol; 2019 Mar; 36(2):242-246. PubMed ID: 30762251
[TBL] [Abstract][Full Text] [Related]
68. Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3.
Bellus GA; Bamshad MJ; Przylepa KA; Dorst J; Lee RR; Hurko O; Jabs EW; Curry CJ; Wilcox WR; Lachman RS; Rimoin DL; Francomano CA
Am J Med Genet; 1999 Jul; 85(1):53-65. PubMed ID: 10377013
[TBL] [Abstract][Full Text] [Related]
69. A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation.
Dailey L; Laplantine E; Priore R; Basilico C
J Cell Biol; 2003 Jun; 161(6):1053-66. PubMed ID: 12821644
[TBL] [Abstract][Full Text] [Related]
70. Clinical and radiologic evaluation of a Turkish family with hypochondroplasia and a rare
Ekinci S; Ülger Y; Acar MO; Ceran A; Aycan Z; Fitoz ÖS; Ilgın Ruhi H
J Pediatr Endocrinol Metab; 2022 Aug; 35(8):1097-1101. PubMed ID: 35438268
[TBL] [Abstract][Full Text] [Related]
71. Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation.
Manickam K; Donoghue DJ; Meyer AN; Snyder PJ; Prior TW
Am J Med Genet A; 2014 Jan; 164A(1):243-50. PubMed ID: 24352917
[TBL] [Abstract][Full Text] [Related]
72. The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation.
Meyer AN; Gastwirt RF; Schlaepfer DD; Donoghue DJ
J Biol Chem; 2004 Jul; 279(27):28450-7. PubMed ID: 15105428
[TBL] [Abstract][Full Text] [Related]
73. Hypochondroplasia and Acanthosis nigricans: a new syndrome due to the p.Lys650Thr mutation in the fibroblast growth factor receptor 3 gene?
Castro-Feijóo L; Loidi L; Vidal A; Parajes S; Rosón E; Alvarez A; Cabanas P; Barreiro J; Alonso A; Domínguez F; Pombo M
Eur J Endocrinol; 2008 Sep; 159(3):243-9. PubMed ID: 18583390
[TBL] [Abstract][Full Text] [Related]
74. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
75. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene.
Tavormina PL; Bellus GA; Webster MK; Bamshad MJ; Fraley AE; McIntosh I; Szabo J; Jiang W; Jabs EW; Wilcox WR; Wasmuth JJ; Donoghue DJ; Thompson LM; Francomano CA
Am J Hum Genet; 1999 Mar; 64(3):722-31. PubMed ID: 10053006
[TBL] [Abstract][Full Text] [Related]
76. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.
Bellus GA; Spector EB; Speiser PW; Weaver CA; Garber AT; Bryke CR; Israel J; Rosengren SS; Webster MK; Donoghue DJ; Francomano CA
Am J Hum Genet; 2000 Dec; 67(6):1411-21. PubMed ID: 11055896
[TBL] [Abstract][Full Text] [Related]
77. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.
Krejci P; Murakami S; Prochazkova J; Trantirek L; Chlebova K; Ouyang Z; Aklian A; Smutny J; Bryja V; Kozubik A; Wilcox WR
J Biol Chem; 2010 Jul; 285(27):20644-53. PubMed ID: 20439987
[TBL] [Abstract][Full Text] [Related]
78. Generation of Fgfr3 conditional knockout mice.
Su N; Xu X; Li C; He Q; Zhao L; Li C; Chen S; Luo F; Yi L; Du X; Huang H; Deng C; Chen L
Int J Biol Sci; 2010 Jun; 6(4):327-32. PubMed ID: 20582225
[TBL] [Abstract][Full Text] [Related]
79. [Clinical features and
Zhang HQ; Tao DY; Zhang JJ; Niu HH; Luo JF; Cheng SQ
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Apr; 24(4):405-410. PubMed ID: 35527416
[TBL] [Abstract][Full Text] [Related]
80. Identification of a novel mutation of FGFR3 gene in a large Chinese pedigree with hypochondroplasia by next-generation sequencing: A case report and brief literature review.
Yao G; Wang G; Wang D; Su G
Medicine (Baltimore); 2019 Jan; 98(4):e14157. PubMed ID: 30681580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
